Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology.
Chung, YR; Lee, K; Cho, EH; Lew, HM
Eye (London, England), 24(8):1320-1324, 2010
Eye (London, England)
PURPOSE: We evaluated the effects of intravitreal injection of bevacizumab (Avastin; Novartis, Basel, Switzerland) on blood pressure (BP) in the context of ocular vascular pathology.
METHODS: This study retrospectively examined 135 consecutive patients treated with intravitreal injections of 1.25 mg bevacizumab for retinal vascular disease; there were 61 cases of diabetic retinopathy, 30 of retinal vein occlusion, 35 of choroidal neo-vascularization (CNV), and 9 of other retinal vascular diseases. BP was measured before injection and at 30 min, 1 day, 1 week, 3 weeks, and thereafter monthly over a 6-month period.
RESULTS: In the CNV group, 30-min post-injection systolic values were significantly higher than baseline, and systolic and diastolic values after 1 day, 1 week, and 3 weeks were significantly lower than before injection. No other pressure measurement differed significantly from baseline values in the other groups.
DISCUSSION: Intravitreal bevacizumab injection is safe in terms of its effect on BP, regardless of ocular pathology.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
Total Visit :3,477,537
Total Download :1,455,911
Today View :1,776
Ajou University Medical Information & Media Center 164 Worldcup-ro Yeongtong-gu Suwon 16499 Korea / TEL : 031-219-5312 / FAX : 031-219-5314 Copyright (c) Ajou University Medical Information & Media Center All Rights Reserved. AJOU Open Repository는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.